GB202307096D0 - Method - Google Patents

Method

Info

Publication number
GB202307096D0
GB202307096D0 GBGB2307096.4A GB202307096A GB202307096D0 GB 202307096 D0 GB202307096 D0 GB 202307096D0 GB 202307096 A GB202307096 A GB 202307096A GB 202307096 D0 GB202307096 D0 GB 202307096D0
Authority
GB
United Kingdom
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
GBGB2307096.4A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Achilles Therapeutics PLC
Original Assignee
Achilles Therapeutics UK Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Achilles Therapeutics UK Ltd filed Critical Achilles Therapeutics UK Ltd
Priority to GBGB2307096.4A priority Critical patent/GB202307096D0/en
Publication of GB202307096D0 publication Critical patent/GB202307096D0/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
GBGB2307096.4A 2023-05-12 2023-05-12 Method Pending GB202307096D0 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
GBGB2307096.4A GB202307096D0 (en) 2023-05-12 2023-05-12 Method

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB2307096.4A GB202307096D0 (en) 2023-05-12 2023-05-12 Method

Publications (1)

Publication Number Publication Date
GB202307096D0 true GB202307096D0 (en) 2023-06-28

Family

ID=86872474

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB2307096.4A Pending GB202307096D0 (en) 2023-05-12 2023-05-12 Method

Country Status (1)

Country Link
GB (1) GB202307096D0 (en)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004021995A2 (en) 2002-09-06 2004-03-18 The Government Of The United States Of America, Represented By The Secretary, Departement Of Health And Human Services Immunotherapy with in vitro-selected antigen-specific lymphocytes after nonmyeloablative lymphodepleting chemotherapy
WO2012065086A1 (en) 2010-11-12 2012-05-18 Nektar Therapeutics Conjugates of an il-2 moiety and a polymer
WO2019012296A1 (en) 2017-07-14 2019-01-17 The Francis Crick Institute Limited Analysis of hla alleles in tumours and the uses thereof
WO2021081378A1 (en) 2019-10-25 2021-04-29 Iovance Biotherapeutics, Inc. Gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy
WO2022207925A1 (en) 2021-04-01 2022-10-06 Achilles Therapeutics Uk Limited Identification of clonal neoantigens and uses thereof

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004021995A2 (en) 2002-09-06 2004-03-18 The Government Of The United States Of America, Represented By The Secretary, Departement Of Health And Human Services Immunotherapy with in vitro-selected antigen-specific lymphocytes after nonmyeloablative lymphodepleting chemotherapy
WO2012065086A1 (en) 2010-11-12 2012-05-18 Nektar Therapeutics Conjugates of an il-2 moiety and a polymer
WO2019012296A1 (en) 2017-07-14 2019-01-17 The Francis Crick Institute Limited Analysis of hla alleles in tumours and the uses thereof
WO2021081378A1 (en) 2019-10-25 2021-04-29 Iovance Biotherapeutics, Inc. Gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy
WO2022207925A1 (en) 2021-04-01 2022-10-06 Achilles Therapeutics Uk Limited Identification of clonal neoantigens and uses thereof

Non-Patent Citations (24)

* Cited by examiner, † Cited by third party
Title
"A practical Textbook", SPRINGER-VERLAG, article "Peptide Chemistry"
ARES ET AL., COLD SPRING HARB PROTOC, no. 11, 3 November 2014 (2014-11-03), pages 1139 - 48
BOA ET AL., CANCER INFORMATICS, vol. 13, 2014, pages 67 - 82
DONG ET AL., MATER TODAY BIO, vol. 17, 2022, pages 100474
HALEMARHAM: "THE HARPER COLLINS DICTIONARY OF BIOLOGY", 1991
JURTZ ET AL., J IMMUNOL, vol. 199, 2017, pages 3360 - 3368
KAMMERMEIER ET AL., J MED GENET, vol. 51, no. 11, November 2014 (2014-11-01), pages 748 - 55
KOBOLDT ET AL., GENOME RES, vol. 22, 2012, pages 568 - 576
KOTSIOU ET AL., BLOOD, vol. 128, 2016, pages 72 - 81
LANDAU ET AL., CELL, vol. 152, no. 4, 14 February 2013 (2013-02-14), pages 714 - 26
LEKO ET AL., J IMMUNOL., vol. 202, 2019, pages 3458 - 3467
LEKO ET AL., J. IMMUNOL., vol. 202, 2019, pages 3458 - 3467
LUNDEGAARD ET AL., J IMMUNOL METHODS, vol. 374, 2011, pages 26 - 34
MARDIS, ANNU REV ANAL CHEM, 2013
MCGRANAHAN ET AL., SCIENCE TRANSL MED, vol. 7, no. 283, 15 April 2015 (2015-04-15), pages 283ra54
MCGRANAHAN ET AL., SCIENCE, vol. 351, no. 6280, 25 March 2016 (2016-03-25), pages 1463 - 1469
MEYERSON ET AL., NAT. REV. GENETICS, 2010
PAUKEN ET AL., J EXP MED, vol. 218, no. 4, 2021, pages e20200920
ROBERGE JY, SCIENCE, vol. 269, 1995, pages 202 - 204
ROTH ET AL., NAT METHODS, vol. 11, no. 4, April 2014 (2014-04-01), pages 396 - 398
SINGLETON ET AL.: "DICTIONARY OF MICROBIOLOGY AND MOLECULAR BIOLOGY", 1994, JOHN WILEY AND SONS
SU ET AL., J IMMUNOL, vol. 197, 2016, pages 4163 - 4176
VAN LOO ET AL., PNAS, vol. 107, 2010, pages 16910 - 16915
YAP KL ET AL., CLIN CANCER RES., vol. 20, 2014, pages 6605

Similar Documents

Publication Publication Date Title
GB202307096D0 (en) Method
GB202304744D0 (en) Method
GB202304439D0 (en) Method
GB202304298D0 (en) Method
GB202303653D0 (en) Method
GB202303637D0 (en) Method
GB202302947D0 (en) Method
GB202302144D0 (en) Method
GB202301247D0 (en) Method
GB202301032D0 (en) Method
GB202300905D0 (en) Method
GB202300841D0 (en) Method
GB202219102D0 (en) Method
GB202218893D0 (en) Method
GB202218052D0 (en) Method
GB202217506D0 (en) Method
GB202217510D0 (en) Method
GB202217313D0 (en) Method
GB202217032D0 (en) Method
GB202216610D0 (en) Method
GB202216162D0 (en) Method
GB202214502D0 (en) Method
GB202214328D0 (en) Method
GB202213553D0 (en) Method
GB202212991D0 (en) Method